Age-Stratified Seroprevalence of Respiratory Syncytial Virus: Analysis Using Prefusion F and G Protein Antibodies

Citations

WEB OF SCIENCE

6
Citations

SCOPUS

6

초록

This is a cross-sectional serosurveillance study for RSV. Between June and September of 2021, a total of 150 sera were collected from 30 individuals in each age group (<5, 5–18, 19–49, 50–64, and ≥65 years). Seroprevalence was estimated using enzyme-linked immunosorbent assays targeting two stabilized prefusion F (preF; DS-Cav1 and SC-TM) and G proteins. The overall seroprevalence was low in young children and older adults, despite them having a higher risk of severe RSV infection. There was a remarkable difference in age-stratified seroprevalence rates between anti-preF and anti-G protein antibodies. Given the high disease burden and low seroprevalence in both infants and old adults, RSV vaccination would be crucial for pregnant women and people aged over 60 years. © 2024 by the authors.

키워드

antibody; respiratory syncytial virus; RSV; seroprevalence; VACCINE; IMMUNIZATION; INFECTION; KINETICS; ADULTS; SERUM
제목
Age-Stratified Seroprevalence of Respiratory Syncytial Virus: Analysis Using Prefusion F and G Protein Antibodies
저자
Nham, Eliel; Jang, A-Yeung; Hyun, Hakjun; Yoon, Jin Gu; Noh, Ji Yun; Cheong, Hee Jin; Kim, Woo Joo; Ahn, Ki Bum; Ji, Hyun Jung; Seo, Ho Seong; Bae, Joon-Yong; Park, Man-Seong; Song, Joon Young
DOI
10.3390/vaccines12050513
발행일
2024-05
유형
Article
저널명
Vaccines
권
12
호
5